Moderna’s mRNA-1345 demonstrates 83% efficacy against RSV in adults 60+, positioning it as a frontrunner in next-gen respiratory …
Moderna’s mRNA-1345 demonstrates 83% efficacy against RSV in adults 60+, positioning it as a frontrunner in next-gen respiratory …
Pfizer’s ambitious gene therapy for Duchenne muscular dystrophy fails to meet efficacy targets, prompting strategic retreat and industry-wide …
Semaglutide’s latest trial reveals significant reduction in heart failure hospitalizations, expanding its role in cardiometabolic care.
NIH-supported study demonstrates that turning off the prion protein gene can dramatically reduce toxic build-up, offering hope for …
NIH-backed research reveals that a simple skin test may revolutionize early diagnosis of Parkinson’s and related neurodegenerative disorders.
The biotech firm discontinues its ReFocus-ALZ and ReThink-ALZ trials, marking a major shift in its neurodegenerative disease strategy.
Amgen’s MariTide leads the pack, while other candidates face setbacks in the competitive GLP-1RA landscape.
New molecular imaging techniques show promise in improving cancer surgery precision and outcomes.
Gilead’s twice-yearly injectable PrEP shows near-perfect efficacy, prompting global access initiatives and a rethinking of HIV prevention strategies.
On November 13, 2024, the U.S. Food and Drug Administration (FDA) approved a novel gene therapy for aromatic …
Already a subscriber? Log in